Introduction
Organic nitrates have been recognized by physicians as potent vasodilators and effective therapy for angina pectoris for over 100 years."2 Despite the advent of beta-blockers and calcium channel antagonists in the 1960s the organic nitrates remain important antianginal agents and are well-established as the drugs of choice in acute angina. Recently interest in nitrate therapy has increased as a result of the widespread use of intravenous nitrates in coronary care, and in the management of acute heart failure and because of this, their inclusion in the ISIS-4 study.
The excellent response to acute nitrate administration led to a search for a method ofgiving nitrate therapy prophylactically. Unfortunately initial attempts were disappointing because, in many instances, chronic dosing with either oral or transcutaneous preparations was associated with the development of tolerance and results in significant attentuation of the antianginal effect. This loss of effect threatened to prevent the successful longterm use of an apparently effective and safe form of therapy for patients with angina. This review will therefore focus on the evidence for tolerance, the possible mechanisms which cause it and the therapeutic attempts that have been made to circumvent it.
Historical perspective
Even in the earliest reports of amyl nitrate use in angina pectoris there was evidence that progressively larger doses were required to achieve a satisfactory therapeutic response.' The first report of haemodynamic tolerance was made by Stewart who noted that persistent use ofnitroglycerin (NG) led to attenuation of the side effects of headache and flushing.3 This early clinical observation led to the first major review ofthe subject in 1905 in which Stewart advocated the use of the 'nitrate free' interval as a means of avoiding tolerance. 4 The widespread use of nitrates in the munition factories became a recognized source of industrial exposure amongst those who manufactured nitroglycerin. Elbright5 reported that, although the headaches associated with the production of nitroglycerin rapidly subsided during continued exposure, this 'immunity' was quickly lost outside the working environment. Swartz6 went on to show that the reappearance of symptoms ('Monday head') could be prevented by applying nitrates to the skin or clothing over the weekend. Animal studies have similarly confirmed the development of tolerance in all species tested, both in vivo and in isolated vascular preparations. Furthermore, treatment with one nitrate compound can induce a state of 'cross-tolerance' to other nitrates. 7 The pharmacodynamic effects of organic nitrates occur in all areas of the cardiovascular sytem. It is therefore necessary, when discussing nitrate tolerance, to specifiy which haemodynamic response is being assessed. For example, higher doses ofnitrates are required to dilate the arterial circulation than the venous capacitance vessels.8 The former effect is responsible for the hypotensive action and the headache associated with therapy, while the latter effect is mainly responsible for venous pooling and preload reduction that underlies much ofthe beneficial action in angina pectoris. It is now well-established that there is rapid tolerance to the hypotensive action of nitrates making these drugs ineffective antihypertensive agents.9 However, because functional studies ofthe venous circulation are technically difficult it is not easy to make direct assessments of tolerance to the venous actions of nitrates. Only indirect measurements such as pulmonary capillary wedge pressures and exercise time to angina are available. In addition, since the antianginal effect is not only a reflection of the venodilatation but may also depend to some extent on arterial and coronary vasodilatation,'°it is not surprising that no clear The improvement in exercise tolerance following patch application is seemingly lost within 12 hours of the first patch application.32 However, tolerance to the antianginal effects of the NG patch is by no means a universal finding with many apparently well-conducted studies coming to the opposite conclusion.33 36 To address the problem of tolerance to the NG patch the Food and Drugs Administration multicentre trial was set up in 1985 after the granting of conditional status to these preparations in the USA. 37 The study was randomized, double blind and placebo-controlled in design and involved a total of 562 patients with baseline TWT of 3-7 minutes (Bruce protocol). After initial patch applications of 15 mg/day, significant benefits were noted at 4 hours but the effect had been lost at 24 hours indicating the rapid onset of tolerance. Although TWT improved by a mean of 90 seconds at the end of the active therapy phase, this did not differ significantly from the control group who benefited from a non-specific training effect from the regular exercise tests. The trial design allowed for cohorts ofpatients to have weekly increments in dosage but even up to 150 mg/day no return of antianginal efficacy could be achieved. This clear demonstration ofrapid and complete tolerance was significant in that it involved much greater numbers of patients than previous reports.
There is inconsistency between the results of studies of the efficacy of the NG patch that cannot be explained by uneven plasma levels. A number of other factors may have been important (Table I) . Marked variations exist in the number of patients, the duration of the study, the daily dose of NG and the method of exercise testing.38'39 However, the factor likely to have been of greatest importance was the use of concomitant antianginal therapy. Some studies recruited patients with stable angina who completed the study period using their usual antianginal medication as well as the nitrate patch, 41 The exercise test performance may also be subject to a number of non-drug related influences such as ambient temperature, relationship to food, emotional status and a diurnal rhythm that may be related to autonomic nervous activity. Episodes of silent and symptomatic myocardial ischaemia are more frequent in the early hours of the day and this may explain why, during continuous patch application, the '24 hour test' has been the one least likely to show a significant improvement. This has major implications as the vast majority ofstudies of single patch application have indicated the loss ofefficacy at 24 hours. If there was no diurnal variation to account for then tolerance at 24 hours should persist. However, it has been consistently shown that even after weeks of therapy and consequently near constant NG levels there may be improvements in daytime exercise capacity despite the apparent presence of tolerance prior to the morning patch application. This seems to imply a background influence which at its greatest (24 hours) suppresses any nitrate effect but may allow the benefits of drug treatment at other times (4 hours post application).
Conclusions
Although there has been marked variability in patient selection, concurrent medication and experimental protocol, there seems little doubt that the regular use of organic nitrates of various kinds is associated to a greater or lesser extent with the development of tolerance. Tolerance seems to occur to the antianginal, haemodynamic and side effects of nitrates although the former remains the most contentious issue. Whether the level of nitrate exposure is a predisposing factor or whether there are certain groups protected from the onset of tolerance remains to be determined. It is clear that sustained and even nitrate exposure is most likely to produce tolerance.46 For this reason the longterm benefits of nitrate patches have been a matter of considerable debate, although there are undoubtedly many patients who have benefited from this treatment. When it has been observed, tolerance has usually been apparent within 12-24 hours of the onset of therapy. Such a rapid decline in efficacy is obviously a serious disadvantage in the clinical setting the ultimate aim of therapy is 24 hour anginal prophylaxis. Just as the onset of tolerance is rapid so too is the return to full nitrate responsiveness following the termination of treatment. 24 Mechanisms of nitrate tolerance Although the basis of nitrate tolerance remains incompletely understood, a number of recent studies have helped to clarify the situation. They have suggested that tolerance results from either the activation of counteractive cardiovascular reflexes or altered responsiveness of vascular smooth muscle following prolonged exposure (Table II) . The possibility that tolerance resulted from a change in pharmacokinetics or altered drug handling has been considered but seems most unlikely. There is no evidence for changes in (cGMP) and that the presence of cysteine, a sulphydryl group donor, was essential for this to occur.55 The production of cyclic GMP then appeared to induce smooth muscle relaxation by reducing cytosolic free calcium whether by activating a Ca2"-extrusion ATPase or causing sequestration of calcium in the sarcoplasmic reticulum.56 However, it was the steps between the entry of exogenous nitrates to the smooth muscle cell and the activation of guanylate cyclase that seemed to hold the key to the tolerant state (Figure 1 ). These steps are apparently dependent on the availability of sulphydryl donors.57 '58 These ideas were elaborated by Ignarro et Rudolph was the first to suggest and subsequently demonstrate that the attentuation of haemodynamic responsiveness could be avoided by providing a nitrate-free period.'9 ISDN given in regular 6 hourly doses rapidly resulted in loss of antianginal efficacy. However, when ISDN was taken at 8 am and 1 pm ('eccentric' dosing) giving low night time nitrate levels, post-dose exercise endurance remained improved after a week. A 15 day comparison of intermittent therapy with buccal GTN and regular oral ISDN showed TWT at 1, 3 and 5 hours post-dose remained prolonged compared to placebo on day 15 with the intermittent buccal but not the oral therapy.87 After their clear demonstration of tolerance in patients assigned four times daily ISDN,'7 Parker's group re-examined the problem and found that antianginal efficacy could be preserved if the last one or two daily doses were omitted.'8 However, even with this type of eccentric dosing regimen it seems that the second and third doses are each less effective than the first.88 Since reflex neurohumoral activation may be an important factor in the development of tolerance some investigators have examined the possibility of intervening with angiotensin-converting enzyme inhibitors. The role of captopril deserves special mention, since its effects may not only involve suppression of the renin-angiotension system. Captopril also contains a sulphydryl grouping which, as previously discussed, may potentiate the pharmacodynamic response to nitrates in the tolerant state. A number of reports have confirmed that captopril can to some extent prevent tolerance and potentiate the actions of NG in angina.34", Subjects rendered tolerant to the antianginal effects of ISDN over 3 weeks once again showed improved exercise capacity when captopril was given 1 hour prior to exercise testing.'0' Both captopril and to a lesser extent enalapril reduced haemodynamic tolerance to nitroglycerin patches as assessed by forearm plethysmography.'02 Thus it seems that, although both drugs were effective, captopril's sulphydryl group may confer some advantage over enalapril. In another attempt to separate the two possible effects of captopril, rat aortic rings were prevented from developing tolerance in vitro by both captopril and N-acetyl-cysteine but not enalaprilat. '03 In an isolated perfused heart model (where the effects of systemic vasoactive substances such as angiotensin II are presumably not active) captopril and cysteine but not non-sulphydryl containing converting enzyme inhibitors could act synergistically with ISDN.'4 It has also been shown that captopril has the potential to react with nitric oxide to form S-nitrosocaptopril, a molecule which activates guanylate cyclase to cause smooth muscle relaxation even in the tolerant state.'05 The potential production of a vasodilating product is interesting in view of the current interest in the role of these drugs in influencing local vasomotor control systems.
Diuretics
Since regular nitrate therapy causes plasma volume expansion which may be a factor in producing tolerance,51'52 the use of diuretics to suppress this compensation has also been examined. When given the ISDN, hydrochlorothiazide preserved the initial anti-ischaemic effects offering further support to the fluid retention hypothesis."
Conclusions
There seems little doubt that tolerance to regular nitrate therapy is a real and clinically significant phenomenon. Although our understanding of its causes is not yet complete, there is good evidence for both altered sensitivity of the blood vessel to nitrates as well as the activation of a number of neurohumoral reflexes that may suppress their pharmacological effect. Since tolerance is likely to be multifactorial in aetiology, any single pharmacological intervention is unlikely to prevent it. Whatever its cause tolerance is rapid in onset but also short-lived.24 For this reason intermittent therapy seems to be an attractive solution with good experimental support. However, it is not yet clear as to whether a nitrate-low or nitrate-free interval is more desirable. This question takes on greater importance given the evidence supporting the occurrence of a rebound phenomenon which may be a major hazard in clinical practice. Current research must address the dilemma of providing a safe washout period without jeopardizing the longterm benefits of chronic nitrate therapy.
In the meantime, the available evidence suggests that organic nitrates are still useful agents for antianginal prophylaxis. Whether oral or transcutaneous preparations are prescribed physicians should incorporate a nitrate-low period during each 24 hours for maximum benefit.
